AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38736628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive defusion techniques
Number of subjects: 70
Study 38736628 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 38736736 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference-delivered group Cognitive Behavioral Stress Management (V-CBSM)
Number of subjects: 0
Study 38737002 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly subcutaneous semaglutide 1.0 mg
Number of subjects: 64
Study 38737002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 38737110 — intervention group
Group type: COMPARATOR
Intervention: Higher PHR (PHR-H) with non-DM
Number of subjects: 56316
Study 38737110 — intervention group
Group type: COMPARATOR
Intervention: Higher PHR (PHR-H) with DM
Number of subjects: 56316
Study 38737110 — intervention group
Group type: COMPARATOR
Intervention: Lower PHR (PHR-L) with DM
Number of subjects: 56316
Study 38737349 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial photobiomodulation (tPBM) - Pulses of near-infrared light (40 Hz, 850 nm) delivered noninvasively twice a week for eight weeks
Number of subjects: 30
Study 38737405 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized Pediatric Palliative Care (SPPC) team support
Number of subjects: 301
Study 38737405 — intervention group
Group type: COMPARATOR
Intervention: Generalist PPC without SPPC support
Number of subjects: 301
Study 38737429 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine
Number of subjects: 144
Study 38737429 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir Alafenamide-based regimen
Number of subjects: 144
Study 38737600 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy (CIRT) with RBE-weighted fraction doses of 8.1-10.5 Gy, total doses 32.4-42.0 Gy, performed every other day in four fractions
Number of subjects: 20
Study 38737708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release carvedilol (carvedilol-SR)
Number of subjects: 100
Study 38737708 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 38737762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support adjusted to obtain PMI closest to -1, 0, +1, +2, and +3 cm H2O
Number of subjects: 22
Study 38737762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support adjustment according to PMI target
Number of subjects: 22
Study 38737792 — intervention group
Group type: EXPERIMENTAL
Intervention: ipilimumab-containing regimens
Number of subjects: 112
Study 38737792 — intervention group
Group type: EXPERIMENTAL
Intervention: nivolumab arm
Number of subjects: 112
Study 38737792 — intervention group
Group type: EXPERIMENTAL
Intervention: ipilimumab-exposed cases
Number of subjects: 112
Study 38737792 — intervention group
Group type: EXPERIMENTAL
Intervention: rash (irAE type)
Number of subjects: 112
Study 38737792 — intervention group
Group type: EXPERIMENTAL
Intervention: liver toxicity (irAE type)
Number of subjects: 112
Study 38737891 — intervention group
Group type: EXPERIMENTAL
Intervention: mFICare (Mobile-enhanced Family Integrated Care)
Number of subjects: 9
Study 38737981 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-applied psychotherapy with psychotherapeutic telephone support
Number of subjects: 110
Study 38737981 — intervention group
Group type: COMPARATOR
Intervention: Self-applied psychotherapy without telephone support (unguided)
Number of subjects: 110
Study 38738598 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate 200 mg daily for 8 weeks
Number of subjects: 12
Study 38738683 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirsevimab
Number of subjects: 0
Study 38738695 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCC-tool used during routine consultations (intervention group)
Number of subjects: 237
Study 38738695 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 237
Study 38738780 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation for 14 days
Number of subjects: 20
Study 38738780 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 20
Study 38738780 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 20
Study 38739062 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Peripheral Nerve Stimulation (PNS)
Number of subjects: 41
Study 38739062 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham) stimulation
Number of subjects: 41
Study 38739079 — intervention group
Group type: EXPERIMENTAL
Intervention: Aficamten (starting dose 5 mg, maximum dose 20 mg)
Number of subjects: 282
Study 38739079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 38739079 — intervention group
Group type: EXPERIMENTAL
Intervention: Aficamten
Number of subjects: 282
Study 38739079 — intervention group
Group type: COMPARATOR
Intervention: Aficamten and Placebo
Number of subjects: 282
Study 38739118 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg once weekly for 52 weeks
Number of subjects: 1145
Study 38739123 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity care (HIC) - rapid uptitration of heart failure GDMT to 100% of recommended doses within 2 weeks of discharge and 4 scheduled outpatient visits over 2 months after discharge
Number of subjects: 1078
Study 38739123 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1078
Study 38739215 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab
Number of subjects: 1407
Study 38739215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1407
Study 38739305 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping Together for Children after Trauma (ST-CT)
Number of subjects: 82
Study 38739305 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PTSS and depressive symptoms
Number of subjects: 82
Study 38739305 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraumatic cognitions and exposure to interpersonal trauma
Number of subjects: 82
Study 38739306 — intervention group
Group type: EXPERIMENTAL
Intervention: Back2School (B2S), a modular transdiagnostic cognitive behavioral therapy (CBT) for SAPs, with an average of 15.0 hours of intervention (SD=3.9) over three months.
Number of subjects: 152
Study 38739306 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU), comprising public and/or private intervention services, with an average of 13.4 hours of intervention (SD=21.6).
Number of subjects: 152
Study 38739382 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (micronized microencapsulated ferric pyrophosphate), 1 mg/kg, once daily from age 4 to 9 months.
Number of subjects: 221
Study 38739382 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin), once daily from age 4 to 9 months.
Number of subjects: 221
Study 38739392 — intervention group
Group type: EXPERIMENTAL
Intervention: True Acupuncture (TA)
Number of subjects: 258
Study 38739392 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 258
Study 38739422 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate-free high-concentration adalimumab-adbm
Number of subjects: 0
Study 38739422 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of adalimumab-adbm
Number of subjects: 0
Study 38739429 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized regular messages and access to interactive chatting through IM apps for 3 months.
Number of subjects: 700
Study 38739429 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging in chat sessions with SC advisors within the intervention group.
Number of subjects: 700
Study 38739429 — intervention group
Group type: COMPARATOR
Intervention: Control group received 26 SMS text messages focusing on general health.
Number of subjects: 700
Study 38739581 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based violence prevention education
Number of subjects: 432
Study 38739581 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 432
Study 38739584 — intervention group
Group type: EXPERIMENTAL
Intervention: Vega PS System
Number of subjects: 84
Study 38739615 — intervention group
Group type: EXPERIMENTAL
Intervention: State-of-the-art periodontal treatment during pregnancy
Number of subjects: 600
Study 38739615 — intervention group
Group type: COMPARATOR
Intervention: Periodontal treatment after giving birth
Number of subjects: 600
Study 38739766 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic ablation of mechanoreceptors before SCI
Number of subjects: 0
Study 38739766 — intervention group
Group type: COMPARATOR
Intervention: Genetic ablation of mechanoreceptors after SCI
Number of subjects: 0
Study 38739766 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-nerve preparations of contusion SCI mice 7 days after injury
Number of subjects: 0
Study 38739766 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing in human SCI subjects
Number of subjects: 0
Study 38740027 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (lopinavir 400 mg twice daily + ritonavir 100 mg twice daily)
Number of subjects: 210
Study 38740027 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (raltegravir 400 mg twice daily)
Number of subjects: 210
Study 38740027 — intervention group
Group type: COMPARATOR
Intervention: Triple nucleoside reverse transcriptase inhibitor (NRTI) group (tenofovir 245 mg once daily + emtricitabine 200 mg once daily + zidovudine 250 mg twice daily)
Number of subjects: 210
Study 38740027 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted lopinavir group
Number of subjects: 210
Study 38740027 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir group
Number of subjects: 210
Study 38740030 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles
Number of subjects: 132
Study 38740030 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 132
Study 38740044 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and chemotherapy
Number of subjects: 335
Study 38740044 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 335
Study 38740133 — intervention group
Group type: EXPERIMENTAL
Intervention: Anapen (BioProject)
Number of subjects: 68
Study 38740133 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiPen (Mylan)
Number of subjects: 68
Study 38740133 — intervention group
Group type: EXPERIMENTAL
Intervention: Jext (ALK)
Number of subjects: 68
Study 38740133 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerade (Medeca)
Number of subjects: 68
Study 38740133 — intervention group
Group type: COMPARATOR
Intervention: Compression
Number of subjects: 68
Study 38740133 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 68
Study 38740133 — intervention group
Group type: EXPERIMENTAL
Intervention: Older men
Number of subjects: 68
Study 38740133 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity-related variables
Number of subjects: 68
Study 38740271 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence age estimation from transthoracic echocardiography
Number of subjects: 319
Study 38740271 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence sex prediction from transthoracic echocardiography
Number of subjects: 319
Study 38740271 — intervention group
Group type: EXPERIMENTAL
Intervention: Age prediction ≥5 years vs chronologic age
Number of subjects: 319
Study 38740297 — intervention group
Group type: EXPERIMENTAL
Intervention: Home health aides intervention
Number of subjects: 6000000
Study 38740298 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured approach and checklist for assessing site readiness to contribute EHR data
Number of subjects: 5451
Study 38740298 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of infrastructure, data procurement, and cost of obtaining study data
Number of subjects: 5451
Study 38740298 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigorous, prospective vetting of data quality and infrastructure
Number of subjects: 5451
Study 38740493 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdafitinib alone
Number of subjects: 13
Study 38740493 — intervention group
Group type: COMPARATOR
Intervention: Erdafitinib with carbamazepine
Number of subjects: 13
Study 38740496 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents living with obesity (ALwO)
Number of subjects: 1200
Study 38740496 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of ALwO
Number of subjects: 1200
Study 38740496 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professionals (HCPs)
Number of subjects: 1200
Study 38740499 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (LDN) starting at 1 mg daily, up-titrated to 4.5 mg daily or maximum tolerated dose over 16 weeks.
Number of subjects: 160
Study 38740499 — intervention group
Group type: COMPARATOR
Intervention: Placebo starting at 1 mg daily, up-titrated to 4.5 mg daily or maximum tolerated dose over 16 weeks.
Number of subjects: 160
Study 38740499 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (LDN)
Number of subjects: 160
Study 38740499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 38740532 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity care (HIC) consisting of rapid up-titration of guideline-directed medical therapy (GDMT) and close follow-up
Number of subjects: 1078
Study 38740532 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1078
Study 38740532 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity care (HIC)
Number of subjects: 1078
Study 38740618 — intervention group
Group type: EXPERIMENTAL
Intervention: e-APA (adapted physical activity program)
Number of subjects: 35
Study 38740618 — intervention group
Group type: COMPARATOR
Intervention: e-HE (health education program)
Number of subjects: 35
Study 38740702 — intervention group
Group type: EXPERIMENTAL
Intervention: AYA cancer survivors
Number of subjects: 3776
Study 38740702 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related conditions reported
Number of subjects: 3776
Study 38740702 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with health-related conditions
Number of subjects: 3776
Study 38740817 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherogenic index of plasma (AIP) increase (per-0.1 unit) in non-AMI patients
Number of subjects: 10735
Study 38740817 — intervention group
Group type: EXPERIMENTAL
Intervention: High platelet reactivity (HPR)
Number of subjects: 10735
Study 38740817 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherogenic index of plasma (AIP) levels
Number of subjects: 10735
Study 38740901 — intervention group
Group type: EXPERIMENTAL
Intervention: High-ELS group
Number of subjects: 163
Study 38740901 — intervention group
Group type: COMPARATOR
Intervention: No-ELS and moderate-ELS groups
Number of subjects: 163
Study 38740901 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 163
Study 38740993 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide
Number of subjects: 17604
Study 38740993 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17604
Study 38740994 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional distress (ED) present
Number of subjects: 227
Study 38740994 — intervention group
Group type: COMPARATOR
Intervention: Emotional distress (ED) absent
Number of subjects: 227
Study 38741101 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 255
Study 38741174 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified balanced energy and protein (BEP) supplementation
Number of subjects: 240
Study 38741174 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrient supplements (MMS)
Number of subjects: 240
Study 38741218 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical left atrial appendage (LAA) closure during open-heart surgery
Number of subjects: 0
Study 38741218 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38741375 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib
Number of subjects: 45
Study 38741375 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with immune checkpoint inhibitors (ICIs)
Number of subjects: 45
Study 38741375 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with ICIs
Number of subjects: 45
Study 38741385 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person intervention
Number of subjects: 415
Study 38741385 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote intervention
Number of subjects: 415
Study 38741607 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) 50 μg once daily, adjusted based on albumin-corrected serum calcium levels
Number of subjects: 22
Study 38741607 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) 50 μg once daily
Number of subjects: 22
Study 38741776 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint cancer screening
Number of subjects: 5506
Study 38741776 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint cancer screening with good compliance
Number of subjects: 5506
Study 38741776 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint cancer screening with poor compliance
Number of subjects: 5506
Study 38741776 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5506
Study 38741917 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic support (3 USD/month for girls, 35 USD/year for guardians, up to 150 USD/year for school fees)
Number of subjects: 4110
Study 38741917 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic support plus community dialogue
Number of subjects: 4110
Study 38741917 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4110
Study 38741917 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic support
Number of subjects: 4110
Study 38742219 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume control
Number of subjects: 0
Study 38742219 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure control
Number of subjects: 0
Study 38742219 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive pressure control
Number of subjects: 0
Study 38742491 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual FFR pullbacks used to calculate PPG; primary outcome of optimal revascularization defined as an FFR ≥0.88 after PCI.
Number of subjects: 993
Study 38742509 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography Angiography (CTA)
Number of subjects: 145
Study 38742522 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary embolism (CE) in patients with STEMI and AF (group A)
Number of subjects: 2292
Study 38742522 — intervention group
Group type: COMPARATOR
Intervention: Atherosclerotic cause in patients with STEMI and AF (group B)
Number of subjects: 2292
Study 38742522 — intervention group
Group type: COMPARATOR
Intervention: Patients without AF and CE (group C)
Number of subjects: 2292
Study 38742554 — intervention group
Group type: EXPERIMENTAL
Intervention: Veil sparing HoLEP (VS-HoLEP)
Number of subjects: 180
Study 38742554 — intervention group
Group type: COMPARATOR
Intervention: Standard HoLEP (St-HoLEP)
Number of subjects: 180
Study 38742577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided access
Number of subjects: 544
Study 38742577 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided access
Number of subjects: 544
Study 38742581 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-coated balloon (BCB)
Number of subjects: 280
Study 38742581 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-coated balloon (PCB)
Number of subjects: 280
Study 38742842 — intervention group
Group type: EXPERIMENTAL
Intervention: CSCT
Number of subjects: 129
Study 38742842 — intervention group
Group type: COMPARATOR
Intervention: VUIMT
Number of subjects: 129
Study 38742842 — intervention group
Group type: COMPARATOR
Intervention: Open Surgery
Number of subjects: 129
Study 38742855 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigued patients
Number of subjects: 59
Study 38742855 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 survivors
Number of subjects: 59
Study 38742855 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 59
Study 38742915 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 209
Study 38742915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 38742940 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-based virtual reality (VR-BF)
Number of subjects: 23
Study 38743047 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool from vaginally seeded infants
Number of subjects: 0
Study 38743047 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) seeding
Number of subjects: 0
Study 38743059 — intervention group
Group type: EXPERIMENTAL
Intervention: Plitidepsin
Number of subjects: 54
Study 38743059 — intervention group
Group type: COMPARATOR
Intervention: Control (non-treated patients)
Number of subjects: 54
Study 38743075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative injection of bupivacaine into the obturator membrane
Number of subjects: 22
Study 38743075 — intervention group
Group type: COMPARATOR
Intervention: No injection (control)
Number of subjects: 22
Study 38743040 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic surgery in low-to-middle-HDI countries
Number of subjects: 4223
Study 38743040 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic surgery in high-HDI countries
Number of subjects: 4223
Study 38743040 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic surgery in very high-HDI countries
Number of subjects: 4223
Study 38743040 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pancreatic surgery outcomes
Number of subjects: 4223
Study 38743040 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure-to-rescue rate in low-to-middle-HDI countries
Number of subjects: 4223
Study 38743040 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure-to-rescue rate in very high-HDI countries
Number of subjects: 4223
Study 38743040 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications of any severity
Number of subjects: 4223